STOCK TITAN

Ionis Pharmaceuticals, Inc. - IONS STOCK NEWS

Welcome to our dedicated page for Ionis Pharmaceuticals news (Ticker: IONS), a resource for investors and traders seeking the latest updates and insights on Ionis Pharmaceuticals stock.

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) is a leading biotechnology company headquartered in Carlsbad, California. Founded in 1989, Ionis has been pioneering the discovery and development of antisense drugs, with an impressive portfolio of over 1300 patents. Ionis focuses on creating innovative RNA-targeted therapies for complex diseases, particularly in the areas of cardiovascular, metabolic, neurological, and rare genetic disorders.

Ionis has successfully brought several groundbreaking medicines to market. Notable achievements include the development of Spinraza, in collaboration with Biogen, which was launched in 2016 to treat spinal muscular atrophy, a rare neuromuscular disorder. In 2023, Biogen also launched Qalsody for ALS, further extending the impact of Ionis' antisense technology.

Through its cardiovascular-focused subsidiary, Akcea Therapeutics, Ionis has introduced drugs like Tegsedi for ATTR amyloidosis and Waylivra in Europe for cardiology indications. The company continues to advance its pipeline with promising candidates such as olezarsen, an investigational RNA-targeted therapy for familial chylomicronemia syndrome (FCS). Ionis' ongoing Phase 3 trials for olezarsen have shown promising results, with significant reductions in triglyceride levels and improvements in related health outcomes.

Ionis' commitment to innovation and patient care is also evident in its robust financial health and strategic partnerships. With a deep understanding of disease biology and cutting-edge technology, Ionis continues to drive advancements in RNA therapies and gene editing, aiming to deliver life-changing medicines for patients around the world.

Recently, Ionis announced positive clinical trial results for several of its investigational drugs and plans to pursue regulatory approvals for these therapies. The company's pipeline is well-positioned to address unmet medical needs in various therapeutic areas, promising a steady flow of new treatments in the coming years.

For more detailed information about Ionis Pharmaceuticals, its products, and career opportunities, visit their official website at www.ionispharma.com.

Rhea-AI Summary

Ionis Pharmaceuticals has announced a significant royalty agreement with Royalty Pharma, involving an upfront payment of $500 million and potential milestones of up to $625 million. This deal allows Royalty Pharma to acquire an interest in Ionis' royalties from SPINRAZA and pelacarsen, while Ionis retains the majority of royalties and milestone payments from Novartis. The investment aims to bolster Ionis' late-stage programs and innovative genetic medicines pipeline, highlighting confidence in the commercial potential of both therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.07%
Tags
none
-
Rhea-AI Summary

Ionis Pharmaceuticals, based in Carlsbad, California, announced that Brett P. Monia, Ph.D., will present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 9:45 a.m. PT (12:45 p.m. ET). The presentation will include a company overview followed by a Q&A session. A live webcast will be available on the Ionis website, with a replay accessible within 48 hours. Ionis has over 30 years of experience in RNA-targeted therapy and currently offers three marketed medicines alongside a robust late-stage pipeline.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.44%
Tags
conferences
-
Rhea-AI Summary

On December 5, 2022, Ionis Pharmaceuticals announced the acceptance of its marketing authorization application (MAA) for tofersen by the European Medicines Agency (EMA) to treat SOD1-ALS. This follows the FDA's acceptance earlier in 2022, with a PDUFA date set for April 25, 2023. If approved, tofersen will be the first therapy targeting a genetic cause of ALS, which affects around 2% of ALS patients globally. The MAA includes data from several studies, and Biogen will maintain its early access program for tofersen across 34 countries.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.32%
Tags
none
Rhea-AI Summary

Ionis Pharmaceuticals partners with Metagenomi to bolster its gene editing capabilities using Metagenomi's advanced systems. This collaboration aims to explore eight genetic targets, with initial research focused on four. Ionis will pay $80 million upfront, with potential milestone payments. The partnership aims to enhance therapeutic options, potentially transforming chronic therapies into curative treatments. A webcast will detail this announcement on Nov. 14, 2022, at 8 a.m. ET.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.83%
Tags
partnership
-
Rhea-AI Summary

Ionis Pharmaceuticals (Nasdaq: IONS) reported positive interim results from a Phase 2 open-label extension study of donidalorsen for hereditary angioedema (HAE). After one year of treatment, patients experienced a 95% mean reduction in HAE attacks, with 99.6% of study days being attack-free. No new safety issues were identified, and adverse events did not lead to study discontinuation. The encouraging data were presented at the ACAAI Annual Meeting, reinforcing donidalorsen's potential as a leading HAE treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Ionis Pharmaceuticals (Nasdaq: IONS) announced participation in several upcoming investor conferences. Key events include:

  • Guggenheim 4th Annual Immunology and Neurology Day on November 14, 2022
  • Stifel 2022 Healthcare Conference on November 15, 2022
  • 5th Annual Evercore ISI HealthCONx and Piper Sandler 34th Annual Healthcare Conference on November 29, 2022
  • Nasdaq 47th Investor Conference and BMO 2022 Growth & ESG Conference on December 7, 2022

Live webcasts and replays will be available on Ionis’ website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.6%
Tags
conferences
Rhea-AI Summary

Ionis Pharmaceuticals (NASDAQ: IONS) reported a 20% revenue increase for Q3 2022, totaling $160 million, driven by significant partner payments across various programs. Operating expenses remained stable at $219 million, while the net loss decreased to $47 million, reflecting improved operational efficiency. The company has increased its cash guidance to approximately $2.0 billion. Notably, positive Phase 3 study data for eplontersen and new facility construction underscore Ionis's growth potential. The company reaffirmed its annual guidance for revenue and expenses.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.92%
Tags
-
Rhea-AI Summary

Ionis Pharmaceuticals announced that GSK presented positive results from the Phase 2b B-Clear study of bepirovirsen, an investigational treatment for chronic hepatitis B virus (CHB). The study demonstrated sustained clearance of hepatitis B surface antigen (HBsAg) and HBV DNA in patients for 24 weeks post-treatment. GSK plans to move bepirovirsen into Phase 3 trials in the first half of 2023. Initial findings suggest better responses in patients with low baseline HBsAg levels.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.54%
Tags
-
Rhea-AI Summary

Ionis Pharmaceuticals presented positive Phase 2 results for IONIS-FB-LRx in treating immunoglobulin A nephropathy (IgAN), achieving a 44% mean reduction in proteinuria after 6 months. The study maintained kidney function in all patients and showed robust reductions in plasma complement Factor B and urinary complement fragment Ba. Roche plans to advance IONIS-FB-LRx into Phase 3 development in H1 2023, addressing a significant unmet medical need in IgAN treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.14%
Tags
Rhea-AI Summary

Ionis Pharmaceuticals announced positive Phase 2b results for fesomersen presented at Kidney Week 2022. This investigational medicine targets Factor XI reduction to prevent thrombosis in patients on hemodialysis. The study showed no increased risk of major bleeding, achieving median FXI reductions of 53.1%, 72.2%, and 86.6% across different doses. Additionally, incidences of dialysis circuit clotting and AV-access thrombosis decreased significantly. Ionis will regain rights to fesomersen from Bayer and is seeking a new partner for its market delivery.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.61%
Tags
none

FAQ

What is the current stock price of Ionis Pharmaceuticals (IONS)?

The current stock price of Ionis Pharmaceuticals (IONS) is $35.63 as of December 20, 2024.

What is the market cap of Ionis Pharmaceuticals (IONS)?

The market cap of Ionis Pharmaceuticals (IONS) is approximately 5.5B.

What does Ionis Pharmaceuticals specialize in?

Ionis Pharmaceuticals specializes in the discovery and development of antisense drugs to treat complex diseases, focusing on cardiovascular, metabolic, neurological, and rare diseases.

Where is Ionis Pharmaceuticals located?

Ionis Pharmaceuticals is headquartered in Carlsbad, California.

What are some key products developed by Ionis Pharmaceuticals?

Key products include Spinraza for spinal muscular atrophy, Qalsody for ALS, Tegsedi for ATTR amyloidosis, and Waylivra for cardiology in Europe.

What is the latest development in Ionis' pipeline?

Ionis is advancing olezarsen, an investigational therapy for familial chylomicronemia syndrome, which has shown promising Phase 3 trial results.

Who are some of Ionis' key partners?

Ionis has strategic partnerships with companies like Biogen and AstraZeneca, helping to bring their innovative therapies to market.

How does Ionis Pharmaceuticals contribute to RNA therapy innovation?

Ionis is a pioneer in RNA-targeted therapies, driving advancements in antisense technology and gene editing to develop treatments for serious diseases.

What is olezarsen and what does it treat?

Olezarsen is an RNA-targeted investigational medicine being developed to treat familial chylomicronemia syndrome (FCS) by reducing triglyceride levels.

How can I learn more about career opportunities at Ionis Pharmaceuticals?

Visit the Ionis Pharmaceuticals website at www.ionispharma.com for more information on career opportunities and to apply for open positions.

What recent clinical trials has Ionis Pharmaceuticals announced?

Ionis recently announced positive results from trials involving olezarsen for FCS and donidalorsen for hereditary angioedema, among others.

How does Ionis Pharmaceuticals support patients with rare diseases?

Ionis develops targeted therapies for rare diseases, providing innovative treatments where few or no options previously existed, significantly improving patient outcomes.

Ionis Pharmaceuticals, Inc.

Nasdaq:IONS

IONS Rankings

IONS Stock Data

5.55B
154.36M
0.77%
103.25%
7%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CARLSBAD